Socioeconomic Status and LVAD Outcomes
Values are summarized as number (%) or median (interquartile range). BMI indicates body mass index; CKD, chronic kidney disease; GFR, glomerular filtration rate; HD, hemodialysis; ICD, implantable cardiac defibrillator; LVAD, left ventricular assist device; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; and PVR, pulmonary vascular resistance. Socioeconomic Status and LVAD Outcomes Pleasanton, CA) and Heartware HVAD (Heartware, Framingham, MA). Patients who required temporary left-sided mechanical circulatory support, biventricular assist device, or total artificial heart were excluded from the analysis. The primary end point was freedom from death or delisting while on LVAD support. Secondary end points included death while on LVAD support, delisting while on LVAD support, complications (thromboembolism, device infection, device malfunction, or life-threatening ventricular arrhythmia) requiring UNOS listing status upgrade, and post-transplant survival. Bridge to transplantation was the ultimate strategy for all patients.
SES was measured using the Agency for Healthcare Research and Quality SES index. The Agency for Healthcare Research and Quality SES index is a measure of neighborhood SES and was generated using the following Zip-code-level Census variables: percentage of people in the labor force who are unemployed, percentage of people living below poverty level, median household income, median value of owner-occupied dwellings, percentage of people ≥25 years of age with <12th grade education, percentage of people ≥25 years of age completing ≥4 years of college, and percentage of households that average ≥1 people per room (Data Supplement). 11 The SES index for this study was calculated using data from the 2014 American Community Survey and has been previously used. [12] [13] [14] The study was submitted to the Institutional Review Board of Columbia University Medical Center and was determined to be exempt from review.
Statistical Analysis
Demographic and clinical variables were summarized with standard descriptive statistics and expressed as median (with interquartile range) for skewed continuous variables and count (with percentage) for categorical variables. Group comparisons were made with the χ 2 and the Kruskal-Wallis tests where appropriate. Kaplan-Meier survival analysis and univariate and multivariable Cox proportional hazards regression were performed to determine survival statistics with Dunnett test applied for pairwise comparisons. Cause-specific hazard models were created, and cumulative incidence functions were calculated with death and delisting alternating as a competing event. A 2-tailed P value of <0.05 was considered significant. Analyses were performed using SAS version 9.4 (SAS Institute, Inc, Cary, NC).
Results
During the study period, 3361 patients met inclusion criteria. The Heartmate II was the predominant LVAD used among the study population (84%). After grouping patients into quartiles based on SES index score, demographic variables differed as anticipated: the top quartile was more educated, had a higher median income, had a greater proportion with private insurance, was more likely to be white or Asian, and was slightly older ( Table 1) . Clinical characteristics were similar across all quartiles except diabetes mellitus was less common, and body mass index was slightly less among those with a higher SES index score. A greater proportion of those in the highest SES quartile had the lowest functional status at listing. Finally, patients in the top SES quartile were less likely to have an LVAD in place at the time of transplant listing and had a shorter time on LVAD support.
A total of 681 patients experienced death or delisting while on LVAD support. Between SES quartiles, there was no difference in event-free survival (Figure 1 , P=0.30). Analysis of individual determinants of SES (education level, household income, type of insurance, and race) failed to demonstrate that any were significant predictors of the composite end point ( Figure 2 ). Competing risks analysis was performed for all patients ( Heart transplantation occurred for 2402 (71.5%) patients during the study period. The incidence of transplantation did not differ by SES, although the median time from LVAD implantation to transplantation was longer for the lowest SES quartile (Table 1) . For the entire cohort, 1-and 2-year post-transplant survival was 89.9% and 86.2%, respectively. When stratified by SES index quartiles, patients in the lowest quartile had a 29% to 41% increased risk of post-transplant graft loss (87.3% 1 year and 82.2% 2 years, P<0.03; Figure 4 ) compared with those in higher SES quartiles. However, no individual SES determinant (education level, income, race, or insurance type) was an independent predictor of post-transplant graft loss ( Figure I in the Data Supplement). Adjusting for age, 15 renal dysfunction, 15 device infection, 16, 17 and duration of LVAD support 18, 19 (previously reported pretransplant causes of decreased bridge to transplantation post-transplant survival) in addition to ischemic time, allograft rejection requiring hospitalization, and post-transplant hospitalizations for infection 15 
Discussion
Socioeconomic disparities exist in healthcare in the United States. These disparities extend to Stage D heart failure with differences in multiple listing before heart transplantation 14 and survival and rejection after transplantation. 7 This study examined the impact that SES and its determinants SES had on patients bridged to transplantation with an LVAD and resulted in 3 notable findings. First, all patients regardless of SES had similar freedom from death or delisting on LVAD support. Second, patients in the top 2 SES quartiles had an increased risk of death on the waitlist during LVAD support, which was explained by increased clinical acuity and differences in baseline clinical risk factors. Finally, patients in the lowest SES index quartile had an early and sustained decreased post-transplant survival compared with each greater SES index quartile. Implantation of a LVAD leads to improved quality of life, increased exercise tolerance, 20 and improved survival. 21 In this study, SES did not affect freedom from death or delisting while on device support. However, higher SES status was associated with an unadjusted increased risk of death. A plausible explanation is that those of greater SES were clinically different and a higher-risk population, which was the case in this study. Those in the top SES quartile had increased odds of being severely debilitated and hospitalized at the time of listing and on a ventilator at the time of listing. Although clinical acuity at listing accounted for some of the increased risk of death for those with greater SES, a portion remained unexplained. This analysis attempted to account for alternative pathogeneses for the increased risk by controlling for clinical characteristics that increase the difficulty of finding a suitable donor (panel reactive antibody >10%, body mass index, sex, and ABO blood type) and those that signify additional comorbidities (PVR suggesting pulmonary hypertension, implantable cardiac defibrillator presence for chronicity of heart failure, renal dysfunction, age, waitlist time on LVAD support, and device complications). The increased risk of death on LVAD support was no longer significant for higher SES quartiles when adjusting for those clinical differences, suggesting that the listing characteristics may differ based on SES. Patients of lower SES more often had an upfront strategy with LVAD implantation at the time of listing (potentially bridge to decision) and were not as functionally debilitated when compared with those with the highest SES. Whether this was because of earlier engagement in care by those with higher SES or a bias based on SES remains unclear, but merits further exploration.
In this study, SES index was associated with post-transplant outcomes. Patients in the lowest SES quartile had an early and sustained decrease in post-transplant survival, even after controlling for risk factors for post-transplant mortality. This finding is consistent with the impact of SES on pediatric heart transplant recipients 6 and previous analyses of the UNOS database demonstrating an association between public insurance and worse outcomes after kidney, 22 liver, 23 and lung transplantation. 24 Insurance coverage of immunosuppressive drugs is one possible cause for the difference in post-transplant outcomes, as prescription coverage can vary between different types of insurance. In this study, survival was equivalent for all SES during LVAD support when new medications (warfarin, aspirin, or dipyridamole) are not prohibitively expensive. However, post transplantation, when more expensive immunosuppressive drugs ($31 209 annually in 2011) 25 are required, those with low SES had an increased risk of death. Post-transplant care requires frequent follow-up for monitoring of immunosuppressive drug levels and rejection surveillance, which is another potential explanation of this difference. In this study, however, there was no evidence of increased odds of hospitalization for rejection or hospitalization for infection after transplantation among those of lower SES.
Limitations of this study include the retrospective nature of the study. The UNOS data set that was used is high quality in that for all US transplant centers data submission is mandatory by law; however, it is limited to the data collected. As such, several covariates of interest including readmission, bleeding, and serum albumin were not available for analysis. Furthermore, there were missing data. Though, no variable had >1% missing data aside from hemodynamic parameters where ≤15% were missing. Nevertheless, this introduces the potential for bias into the analysis. Similarly, not all complications were able to be captured given the limitations of the UNOS database. The most serious complications that required UNOS status upgrade were captured, however. The study population was also bridge to transplantation because the UNOS database does not include destination therapy patients. Finally, the SES index was calculated using Zipcode-level Census data as some specific SES determinants are not captured by the UNOS database. This has been used as a strategy in many previous analyses of the UNOS database; nonetheless Zip-code-level data were used as a proxy for patient-level data under the presumption that these factors are homogenous within a Zip-code and a patient's Zipcode did not vary.
In conclusion, SES and its determinants did not affect survival to transplantation on LVAD support. Those of higher SES had an unadjusted increased risk of death during LVAD support, although this was because of clinical differences. After transplantation, low SES was associated with worse post-transplant survival. Further study is needed to confirm and understand a differential effect of SES on post-transplant outcomes that was not seen during LVAD support before heart transplantation.
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